secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001193125-26-104218
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics FY2025 net loss $22.4M; cash $13.1M, outlines 2026 milestones for REYOBIQ and CNSide
--------------------------------------------------------------------------------

- Net loss $22.4M ($0.29/shr) vs $13.0M ($1.95/shr) in 2024; operating loss $15.3M vs $14.7M.
- Cash and investments $13.1M at Dec 31, 2025 (up from $3.6M); raised $15M gross in upsized public offering.
- CNSide lab licensed in 49 states; coverage agreements with Humana and UnitedHealthcare reach ~67M lives.
- 2026 milestones: REYOBIQ Phase 2 LM data Q3 2026, GBM data Q4; CNSide target >1,250 annual test orders, breakeven by 2027.
- Secured AMA Category III CPT code for convection-enhanced delivery with REYOBIQ, unlocking market access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526104218/0001193125-26-104218-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000119312526104218/pstv-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-104218

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer